Navignostics raises CHF 7.5M to advance precision cancer medicine

Navignostics uses artificial intelligence (AI) driven software, coupled to single-cell resolved spatial proteomic tumor data to identify the best possible treatment for each cancer patient. The seed round was led by Bruker Invest. Bruker Corporation’s CEO Frank Laukien is particularly impressed by Navignostic's team.

Founded in April 2022 by Jana Fischer, Stephane Chevrier, Andrea Jacobs and Bernd Bodenmiller, Navignostics is leveraging spatial single-cell proteomics to perform advanced analyses of tumor samples. Navignostics aims to guide targeted and immuno-oncology therapy selection tailored towards the individual cancer patient’s tumor phenotype. The proprietary approach will also help accelerate oncology drug development and enable the discovery of companion diagnostic biomarkers.

The spin-off from the University of Zurich announced this week the closing of their seed financing round with an investment of CHF 7.5M. Bruker Invest AG led the oversubscribed round, joined by Think.Health Ventures, Ventura Biomed Investors, and the Zürcher Kantonalbank.

“With this seed financing, we will boost our capacity to engage with clinical, biotech and pharma partners and accelerate the development of our first diagnostic product. We will take a big step in Navignostics’ company expansion by moving our team into our own laboratory and office premises, enabling the establishment of certified processes and further expansion of our world-leading team of scientists and business professionals,” said Dr. Jana Fischer, Co-Founder and CEO of Navignostics.

Dr. Frank Laukien, CEO of Bruker Corporation and also co-chair of the AACR Cancer Evolution working group, commented: “I believe that high-plex spatial single-cell proteomics has enormous potential for precision oncology, and for research towards a better functional understanding of the tumor microenvironment (TME). Navignostics has the innovative and visionary founders and leadership team to advance and translate spatial single-cell proteomics into clinical use for the near-term benefit of the many cancer patients, who may benefit from meaningfully longer progression-free or overall survival.” With 7’500 employees at over 90 locations, Bruker is one of the world's leading analytical instrumentation companies. In 2021, Bruker has generated sales of USD 2.4 billion.

Navignostics strives to provide innovative solutions to identify the best possible treatment for each cancer patient. In addition, Navignostics provides advanced services to pharmaceutical companies to accelerate cancer drug development and contribute to companion diagnostic development. 

(Press release / SK)